HIGHLIGHTS
- who: Ranibizumab . Bevacizumab . and collaborators from the Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA Dalhousie University have published the research: Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines, in the Journal: (JOURNAL)
- how: While the primary analysis of this study did not identify significant differences in risk between the ranibizumab and bevacizumab groups a secondary analysis in which the study population was limited to 40841 newly-treated patients who received bevacizumab or ranibizumab only showed significantly increased risks of all-cause mortality and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.